Community Education
Plain-language materials and conversation starters to share information, answer questions, and counter misinformation.
Developed in honor of World TB Day 2026, this zine demystifies vaccines, TB, and leading TB vaccine candidates. Tapping into optimism for a future TB vaccine and the importance of community care through vaccination, this zine grounds the conversation in what an effective new TB vaccine would look like for communities, how vaccines integrate into the larger TB prevention strategy, and how a new TB vaccine for adults and adolescents could be a powerful tool in the quest to end TB.
The research process from discovery to clinical trials to implementation can be opaque making interpreting results from studies difficult for even a seasoned researcher or activist. This lecture series walks through the fundamentals of research, key terms, and common measures found in clinical trial results; preparing activists and advocates to understand TB vaccine trial results as they emerge over the next several years.
Seven Reasons Why The World Needs New TB Vaccines Advocacy Conversation Starters and Key Messages presents seven key messages that can serve as “conversation starters” when advocating for new TB vaccines across a wide variety of stakeholders. The seven messages together provides a unified backbone for all TB vaccine messaging grounded in evidence-based narratives that resonate with decision-makers that can be adapted for local contexts based on the key interests and needs of unique communities.
TB has plagued humanity for nearly as long as humanity existed. This lecture offers a broad overview of how TB interacts with the human body and society. Covering everything from the TB bacterium itself, to how the immune system responds to TB, how infection becomes TB disease, and even how TB intersects with larger health and societal disparities, this module dives into why TB remains so persistent over the centuries despite our best efforts to end TB.
This cheat sheet designed specifically for community activists gives readers a high level overview of the basic science behind different common vaccine types (i.e., mRNA vaccines, viral vector vaccines). The vaccine types included all represent types of vaccines under development for the TB and the cheat sheet provides examples of well known vaccines for other diseases that use a similar design model. The cheats sheet notes key considerations that influence the efficacy, safety, acceptance, and accessibility of vaccines.
Over one hundred years after the introduction of BCG, the TB Vaccine Pipeline holds the potential for a new TB vaccine. This crash course covers the history, immunology and science behind the development of TB vaccines, and covers the major developments that lead to the opening of recent phase III trials.
The Working Group on New TB Vaccines TB Vaccine Pipeline covers TB vaccine candidates from preclinical proof-of-concept models to post-marketing studies. Candidates for each category can be viewed by latest stage of development, or on a sortable page that filters candidates by certain categories. Follow the pipeline as candidates move along the development pathway towards the goal of entering Phase III trials.
The long awaited results from the PreVenTB trial of two candidate TB vaccines — VPM1002 and Immuvac — were disappointing for the vaccine candidates themselves, but represented a victory for TB vaccine science and community engagement.
Civil society and communities celebrated that the PreVenTB trials represented the largest TB vaccine trial of this century and was funded by high-TB-burden country governments. Further the study was designed to reflect the specific epidemiology of the TB epidemic within India, enrolling populations that stand to benefit the most from a future TB vaccine but were left out of other trials.
Treatment Action Group’s 2026 Tuberculosis Vaccines Pipeline Report surveys major developments in the clinical development of new TB vaccines at this moment of scientific promise and political peril. The pipeline contains 14 candidates and covers vaccines that currently in Phase I, II, or III trials, For each candidate, TAG summarizes the known ongoing, recently completed, or planned clinical trials. Narrative descriptions throughout discuss the notable updates of key candidates that generated the most news over the past year either due to clinical trial results, delays, or the beginning of major new studies.



